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Abstract
Purpose Poly-(-L-glutamylglutamine)–paclitaxel (PGG–
PTX) is a novel polymer-based formulation of paclitaxel
(PTX) in which the PTX is linked to the polymer via ester
bonds. PGG–PTX is of interest because it spontaneously
forms very small nanoparticles in plasma. In mouse
models, PGG–PTX increased tumor exposure to PTX by
7.7-fold relative to that produced by PTX formulated in
Cremophor. In this study, the eYcacy of PGG–PTX was
compared to that of Abraxane, an established nanoparticu-
lar formulation of PTX, in three diVerent tumor models.
Methods EYcacy was quantiWed by delay in tumor
growth of NCI H460 human lung cancer, 2008 human
ovarian cancer and B16 melanoma xenografts growing in
athymic mice following administration of equitoxic doses
of PGG–PTX and Abraxane administered on either a single
dose or every 7 day schedule. Toxicity was assessed by
change in total body weight.
Results The eYcacy and toxicity of PGG–PTX was
shown to increase with dose in the H460 model. PGG–PTX
was »1.5-fold less potent than Abraxane. PGG–PTX pro-
duced statistically signiWcantly greater inhibition of tumor
growth than Abraxane in all three tumor models when mice
were given single equitoxic doses of drug. When given
every 7 days for 3 doses, PGG–PTX produced greater inhi-
bition of tumor growth while generating much less weight
loss in mice bearing H460 tumors.
Conclusion PGG–PTX has activity that is superior to that
of Abraxane in multiple tumor models. PGG–PTX has the
potential to out-perform Abraxane in enhancing the deliv-
ery of PTX tumors while at the same time further reducing
the toxicity of both single dose and weekly treatment
regimens.
Keywords Paclitaxel · Abraxane · Drug delivery · 
Lung cancer · Ovarian cancer · Melanoma
Abbreviations
MTD Maximum tolerated dose
PGA Poly(L-glutamic acid)
PGG Poly(L--glutamylglutamine)
PGG–PTX 70 kDa PGA to which both additional gluta-
mine side chains and PTX have been added
PTX Paclitaxel
Introduction
Paclitaxel (PTX) is eVective for the treatment of a wide
variety of cancers but, because of its limited solubility in
water, it is currently formulated as a concentrated solution
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containing 6 mg PTX/ml Cremophor EL and ethanol (50%
v/v) that must be further diluted before administration.
Cremaphor EL is a biologically and pharmacologically
active compound and its use is associated with acute hyper-
sensitivity reactions [4, 15]. Many investigators have tried
to develop PTX formulations using liposomes, micro-
spheres, micelles, nanoparticle, prodrugs, and polymer-drug
conjugates [4, 24]. One of these, paclitaxel protein-bound
particles for injection (Abraxane), is based on the use of a
nanoparticle made from a mixture of paclitaxel and
albumin and is now marketed for the treatment of breast
cancer. However, the fractional improvement in breast can-
cer progression-free survival was quite modest [5].
Another, CT-2103 (Xyotax), takes advantage of the fact
that paclitaxel can be made more soluble by conjugating it
to the water-soluble polymer poly(L-glutamic acid) [9, 10,
22]. Like Abraxane, CT-2103 exhibits reduced toxicity and
increased eYcacy in preclinical models including paclit-
axel-resistant tumors [1–3,  6,  7,  11–13, 16,  18,  25,  26].
However, despite favorable phase II clinical trial results
[13, 21, 23], three randomized phase III trials in patients
with non-small cell lung cancer failed to demonstrate an
improvement in either progression-free or overall survival
[8, 17, 19] and CT-2103 has not yet received marketing
approval.
We have developed a novel formulation of PTX that uti-
lizes both the ability of a polymer to enhance solubility and
to form nanoparticles with the goal of even further enhanc-
ing the therapeutic eYcacy of PTX. The polymer backbone
of this formulation consists of poly(L-glutamic acid) to
which a glutamate side chain has been added to each mono-
mer in the polymer to create poly(L-glutamylglutamate)
(PGG). As shown in Fig. 1, these both increases the number
of –COOH groups available to interact with water mole-
cules so that solubility is enhanced and approximately dou-
bles the molecular weight of the polymer. When PTX is
conjugated to this polymer to an extent of 35% (w/w) to
create poly-(-L-glutamylglutamine)–paclitaxel (PGG–
PTX), the tendency of the hydrophobic PTX molecules to
interact with each other causes the polymer to collapse to
form a nanoparticle of »20 nm in aqueous solutions as
determined by dynamic light scattering. This particle is
considerably smaller than the nanoparticles that make up
Abraxane (80–120 nm) which may favor both the exit of
this particle from the vascular compartment once it reaches
a tumor, and movement through the tumor extracellular
Xuid.
The eYcacy of PGG–PTX has now been tested in a
panel of murine and human tumor xenografts in which the
activity of PGG–PTX was directly compared to that of
Abraxane when the two drugs were given at equitoxic
doses. We report here that PGG–PTX out-performs Abrax-
ane in several of these models on a single dose schedule,
and that PGG–PTX is substantially less toxic than Abrax-
ane when used on a multidose schedule.
Materials and methods
Chemicals and reagents
Poly-(-L-glutamylglutamine)–paclitaxel (PGG–PTX) was
synthesized from commercially available poly(L-glutamic
acid) sodium salt with a molecular weight of 24,880 Da.
L-glutamic acid di-t.-butyl ester hydrochloride was linked
to each monomer in the polymer using a coupling reagent.
PTX was then conjugated to the poly(L-glutamylglutamate)
using N-(3-dimethylaminopropyl)-N-ethylcarbodiimide. The
PTX content of PGG–PTX was quantiWed and found to be
35.8% (w/w). The PGG–PTX was dissolved in saline at
concentration of 17.5 mg PTX/ml (50 mg total weight/ml).
Fresh stock solutions were prepared on the day of injection.
Commercially available Abraxane (Los Angeles, CA) was
dissolved in saline at concentration of 80 mg/ml. All other
chemicals and reagents were obtained from Sigma Chemi-
cal Co. (St. Louis, MO), Invitrogen/Life Technologies, Inc.
(Carlsbad, CA), Millipore Coorporation (Temecula, CA),
or Hyclone (Logan, UT).
Fig. 1 Structure of PGGA-PTX, a random ester conjugate of
poly(L--glutamylglutamine) and paclitaxel. There are approximately
5 non-conjugated monomer glutamylglutamine units per paclitaxel-
conjugated monomer glutamylglutamine unit
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Cell culture
NCI-H460 and 2008 cells were maintained in RPMI-1640
supplemented with 10% fetal bovine serum containing
100 U/ml penicillin and 100 g/ml streptomycin. B16-F0
cells were grown in DMEM supplemented with 10%
bovine serum, 100 U/ml penicillin and 100 g/ml strepto-
mycin. Cells were split 48 h before inoculation into mice so
that they were in log phase growth when harvested.
EYcacy studies
NCI-H460 and 2008 cells were suspended in serum-free
RPMI 1640 medium, and B16-F0 cells suspended in serum-
free DMEM medium, and then injected subcutaneously. The
inoculum size per site was 4 £ 106 cells for the NCI-H460
cells, 2 £ 106 for the 2008 cells, and 0.5 £ 106 for the B16
cells. NCI-H460 and B16 cells were injected over each shoul-
der and each hip of 6- to 8-week-old female athymic nude
(nu/nu) mice (Charles River lab, Willington, MA) (4 sites per
mouse). The 2008 cells were injected only over both shoul-
ders. Tumors were allowed to grow until they reached an
average volume of 30–40 mm3. Tumor size in mm3 was esti-
mated from the formula (w2 £ l)/2 where “l” is the longest
diameter of the tumor and “w” is the diameter perpendicular to
the longest diameter measured in millimeters. Tumor-bearing
animals were then randomly sorted into 3 groups of 6–10 mice
each. Both Abraxane and PGG–PTX were administered as a
single IP injection. Control animals were injected with saline
in a volume equivalent to the volume of PGG–PTX. The
MTD was deWned as the dose that produced 10% weight loss.
Mice were weighed daily and tumor volumes were measured
every other day until total tumor burden reached 1.5 cm3 at
which time mice were killed. All in vivo studies were per-
formed at the animal facility of University of California San
Diego in accordance with institutional guidelines set out by
Institutional Animal Care and Use Committee (IACUC).
Statistics
The slope of the regression of log (tumor volume) on time
was determined for each individual tumor and the mean of
the slopes of all tumors within a group was compared using
the Student’s t test.
Results
Activity of PGG–PTX in NCI-H460 human lung cancer 
xenograft model as a function of dose
The dose–eVect relationship for PGG–PTX was explored in
mice bearing NCI-H460 lung cancer xenografts. Mice were
inoculated with NCI-H460 cells SC at 4 sites and randomly
assigned to control or experimental groups. A single dose of
PGG–PTX was administered IP when average tumor vol-
ume was 30–40 mm3. Figure 2 shows that there was a well-
deWned progressive increase in tumor growth inhibition as
the dose of PGG–PTX was increased from 100 to 300 mg
PTX/kg. To assess the statistical signiWcance of this diVer-
ence, a plot was made for each individual tumor of the log of
the tumor volume as a function of time. The slope of this
curve was then determined and the mean and standard error
of the slopes of each group was calculated. The mean values
for each group were compared to each other using the Stu-
dent’s t test. This analysis demonstrated that a signiWcant
delay in tumor growth was Wrst detected at a dose of 150 mg
PTX/kg (P = 0.042), and that the signiWcance of the diVer-
ence relative to the untreated mice increased progressively
with dose with P values being 0.006 at 200 mg PTX/kg,
0.0004 at 250 mg PTX/kg and 3.6 £ 10¡7 at 300 mg PTX/kg.
The acute weight loss over the Wrst week after dosing also
increased progressively with dose ranging from 1% at a
dose of 150 mg PTX/kg to 8% at a dose of 250 mg PTX/kg.
Thus, PGG–PTX exhibited signiWcant antitumor activity in
this model even at a dose that caused minimal weight loss,
and both its antitumor activity and toxicity increased in a
well-deWned dose-dependent manner.
Relative eYcacy of PGG–PTX and Abraxane 
in the NCI-H460 human non-small cell lung cancer 
xenograft model
The relative eYcacy of PGG–PTX and Abraxane was
assessed by comparing the eVect of a single maximum
Fig. 2 Tumor growth delay as a function of PGG–PTX dose in mice
bearing NCI-H460 tumors. Saline controls (Wlled circle), PGG–PTX
100 (Wlled diamond), PGG–PTX 150 (Wlled square), PGG–PTX 200
(Wlled triangle), PGG–PTX 250 (Wlled square), PGG–PTX 300 mg
PTX/kg (thick line). Vertical bars §SEM
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tolerated dose of either drug administered by the IP route
on tumor growth delay and weight loss; mice treated with
saline alone served as controls. In nu/nu mice bearing NCI-
H460 tumors, the MTD was 300 mg PTX/kg for PGG–PTX
and 250 mg PTX/kg for Abraxane. As shown in Fig. 3a,
PGG–PTX produced a greater degree of inhibition of tumor
growth than Abraxane. The statistical analysis demon-
strated that PGG–PTX produced signiWcant inhibition of
tumor growth relative to that in the control mice
(P = 0.001) but Abraxane did not (P =0 . 9 2 ) .  A t  d o s e s  t h a t
produced equivalent degrees of acute weight loss, the tumor
growth delay produced by PGG–PTX was superior to that
attained with Abraxane (P = 0.00002). The Wnal estimated
tumor volume on day 23 in the mice treated with PGG–
PTX was only 41% of that in the mice treated with
Abraxane.
Figure 3b shows that Abraxane at a dose of 250 mg/kg
produced a 15 § 6% (SEM) loss of weight with a nadir on
day 5. PGG–PTX at a dose of 300 mg PTX/kg produced the
same degree of weight loss (13 § 6%) with a nadir day 6.
No animals died of toxicity in the PGG–PTX group
whereas there was 1 toxic death among the 6 animals in the
Abraxane group. However, while both drugs produced
equivalent acute reductions in body weight, weight recov-
ery was more rapid following administration of Abraxane.
Mice treated with Abraxane regained their initial body
weight by day 8–9, whereas mice treated with PPG-PTX
required >20 days. This diVerence is consistent with the
observation that PGG–PTX has a much longer plasma half-
life (293 h) in mice than Abraxane (19 h) in the rat [26, 27],
and suggests that the PTX delivered by PGG–PTX remains
in both the tumor and normal tissues for very prolonged
periods of time relative to that delivered by Abraxane.
Relative eYcacy of PGG–PTX and Abraxane in the human 
ovarian 2008 xenograft model
The 2008 ovarian cancer model has been widely used for
the testing of novel polymeric drug delivery systems [14,
20]. The sensitivity of nu/nu mice bearing these tumors was
slightly diVerent than in mice bearing NCI-H460 tumors,
and in this model the MTD for Abraxane was only 200 mg
PTX/kg. As shown in Fig. 4a, both the PGG–PTX at
300 mg PTX/kg and Abraxane at a dose of 200 mg PTX/kg
produced statistically signiWcant degrees of tumor growth
inhibition relative to the growth of tumors in control mice
(P = 0.006 and 0.05, respectively). However, the magni-
tude of the inhibition was substantially greater for PGG–
PTX than for Abraxane and this diVerence between the
eVect of the two drugs was signiWcant (P =0 . 0 2 5 ) .  T h e
Wnal estimated tumor volume on day 91 in the mice treated
with PGG–PTX was only 25% of that in the mice treated
with Abraxane. As shown in Fig. 4b, these doses were equi-
toxic to each other as assessed by the nadir of weight loss
which was 10 § 1% (SEM) for PGG–PTX and 7 § 3%
(SEM) for Abraxane. As was observed in the NCI-H460
model, body weight recovered more rapidly in mice treated
with Abraxane than in those who received PGG–PTX con-
sistent with the diVerence in the plasma half-lives of these
two drugs. There was also a diVerence in body weights after
day 60 that could not be attributed to diVerent numbers of
mice surviving in the 3 groups and whose etiology is not
currently apparent.
Relative eYcacy of PGG–PTX and Abraxane in the murine 
B16 melanoma model
The murine B16 tumor is another model extensively used
for the preclinical assessment of novel drug delivery sys-
tems. In order to permit direct comparisons in the same
species of mouse, the B16 tumors were also grown in nu/nu
mice. In mice bearing B16 tumors, the MTD of PGG–PTX
(350 mg PTX/kg) was higher than in the same mice
bearing NCI-H460 and 2008 tumors but they were more
sensitive to Abraxane whose MTD in this model was just
150 mg PTX/kg. As shown in Fig. 5a, Abraxane at this
Fig. 3 Tumor volume and weight loss as a function of time in mice
bearing NCI-H460 tumors treated with a single IP dose of either saline
(Wlled triangle), PGG–PTX (300 mg PTX/kg) (Wlled diamond) or
Abraxane (250 mg PTX/kg) (Wlled square). Vertical bars §SEM
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dose produced no detectable inhibition of tumor growth. In
contrast, a dose of PGG–PTX that produced approximately
the same degree of acute weight loss demonstrated signiW-
cant tumor growth delay relative to untreated controls
(P = 0.0002) and relative to mice treated with Abraxane
(P = 0.02). The Wnal estimated tumor volume on day 9 in
the mice treated with PGG–PTX was only 43% of that in
the mice treated with Abraxane. As shown in Fig. 5b,
Abraxane at a dose of 150 mg/kg produced 7 § 2% (SEM)
loss of weight with a nadir on day 3. PGG–PTX at a dose
of 350 mg PTX/kg produced the same degree of weight
loss [7 § 3% (SEM)] and the nadir also occurred on day 3.
However, the rate of recovery of body weight was
slower after this dose of PGG–PTX than it was following
Abraxane at 150 mg/kg.
Relative eYcacy of PGG–PTX and Abraxane 
in the NCI-H460 model using a multidose schedule
PTX and Abraxane can be used on either a single dose
schedule or a weekly schedule during the treatment of can-
cer in patients. To compare the relative eYcacy of PGG–
PTX and Abraxane on a weekly schedule, mice inoculated
with NCI-H460 tumors were treated with equitoxic doses
of each drug every 7 days for 3 doses. Preliminary studies
demonstrated that a single IV dose of PGG–PTX at a dose
of 140 mg PTX/kg was equitoxic with Abraxane at a dose
of 40 mg PTX/kg with respect to weight loss, and these
doses were selected for the multidose schedule. Figure 6a
shows that PGG–PTX was more eVective than Abraxane
at slowing tumor growth on this multidose schedule
(P = 0.02). However, the major diVerence between the two
drugs was the toxicity. On this multidose schedule, Abrax-
ane turned out to be much more toxic than PGG–PTX
(Fig. 6b). The 140 mg PTX/kg dose of PGG–PTX pro-
duced only 7 § 3% (SEM) weight loss by day 29 whereas
Abraxane produced a progressive weight loss with each
additional dose that resulted in a weight loss of 19 § 2%
(SEM) of initial body weight. Thus, on this schedule, the
therapeutic ratio of PGG–PTX was substantially better than
that of Abraxane.
Fig. 4 Tumor volume and weight loss as a function of time in mice
bearing human ovarian carcinoma 2008 xenografts treated with a sin-
gle IP dose of either saline (Wlled triangle), PGG–PTX (300 mg PTX/
kg) (Wlled diamond) or Abraxane (200 mg PTX/kg) (Wlled square).
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Fig. 5 Tumor volume and weight loss as a function of time in mice
bearing murine B16 melanomas treated with a single IP dose of either
saline (Wlled triangle), PGG–PTX (350 mg PTX/kg) (Wlled diamond)
or Abraxane (150 mg PTX/kg) (Wlled square). Vertical bars §SEM
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Discussion
Poly-(-L-glutamylglutamine)–paclitaxel (PGG–PTX) is of
interest as a novel drug delivery system for PTX for several
reasons. First, it is unique in being a polymer-based system
that spontaneously forms nanoparticles in aqueous environ-
ments. Ongoing molecular modeling studies suggest that
the hydrophobic interactions between the PTX molecules
randomly distributed along the PGG polymer cause col-
lapse of the polymer strand to form a particle with a hydro-
philic surface and a hydrophobic core. Second, the size of
the nanoparticles as determined by dynamic light scattering
is substantially smaller than those in the Abraxane formula-
tion (»20 vs. 80–120 nm). The large diVerence in size is
likely to translate into important diVerences in the behavior
of the drugs both in the plasma and in tissues. Third, phar-
macokinetic studies in nu/nu mice bearing NCI-H460
tumors indicate that conjugation of PTX to the PGG poly-
mer increased plasma and tumor Cmax, prolonged plasma
half-life and the period of accumulation in tumor, and
reduced washout from the tumor. The plasma exposure to
total taxane produced by PGG–PTX, measured over the
Wrst 340 h after injection, was 23-fold greater than that pro-
duced by unconjugated PTX, and the tumor exposure was
increased by a factor of 7.7-fold [27]. In contrast, Abraxane
increased tumor exposure by only 33% relative to that
attained with Cremophor-based paclitaxel (3632 vs.
2739 nCi h/g) in the MX-1 xenograft model reported by
Desai et al. [3]. The results of the current study provide an
additional reason for interest in PGG–PTX. In all 3 of the
models tested in this study in which a single dose of drug
was used, PGG–PTX out-performed Abraxane with respect
to inhibition of tumor growth when both drugs were given
at doses that produced similar degrees of acute weight loss.
In addition, the magnitude of the increase in eVectiveness
was quite substantial and statistically signiWcant in all 3
models. Perhaps even more importantly, when given every
7 days for 3 doses, PGG–PTX produced greater inhibition
of tumor growth while at the same time causing much less
toxicity than Abraxane. Even while being less eVective, the
40 mg PTX/kg dose of Abraxane produced progressive
weight loss and was not tolerated on a weekly schedule.
Part of the explanation for the diVerence in eYcacy of
PGG–PTX and Abraxane, and for the delayed recovery of
body weight in the mice treated with a single dose of
PGG–PTX, likely lies in their quite diVerent pharmacoki-
netics both in the plasma and in normal and malignant tis-
sues. PGG–PTX was found to be somewhat less potent
than Abraxane with respect to acute toxicity when given
on a single dose schedule. Whereas the MTD for PGG–
PTX was 300–350 mg PTX/kg in all 3 models, the single
dose MTD for Abraxane varied from 150 mg PTX/kg in
the B16 model to 250 mg PTX/kg in the NCI H460 lung
cancer model. It appears that the type of tumor modulates
the toxicity of Abraxane to a greater extent than that of
PGG–PTX, an eVect most likely related to the speciWc
vascular anatomy of each tumor type. The plasma half-life
of Abraxane in mice has not been reported but in the rat it
was found to be 19.0 h; the plasma clearance was 517 ml/
h/kg [26]. In contrast, in pharmacology studies carried out
in nu/nu mice bearing NCI H460 tumors executed in par-
allel with the eYcacy studies reported here, the plasma
half-life of PGG–PTX was found to be 296.2 h and the
clearance only 11.5 ml/h/kg [27]. Whereas Abraxane
increased the total tumor exposure to PTX by only 33%
above that produced by an equitoxic dose of PTX formu-
lated as Taxol in the MX1 tumor model [3], PGG–PTX
increased exposure for the NCI H460 tumors by a factor
of 7.7-fold in the NCI H460 model [27]. Studies directly
comparing the tumor exposure to PTX following injection
of equitoxic doses of PGG–PTX and Abraxane in the
same tumor model have yet to be performed. Neverthe-
less, these data are consistent with the concept that PGG–
PTX is more eYcient at targeting PTX to tumors than
Fig. 6 Tumor volume and weight loss as a function of time in mice
bearing NCI-H460 lung cancers treated every 7 days for 3 doses with
either saline (Wlled triangle), PGG–PTX (140 mg PTX/kg) (Wlled dia-
mond) or Abraxane (40 mg PTX/kg) (Wlled square). Vertical bars
§SEM
0
500
1000
1500
2000
2500
3000
3500
-25
-20
-15
-10
-5
0
5
10
15
0 5 10 15 20 25 30 35
Days Post Administration
Days Post Administration
P
e
r
c
e
n
t
 
o
f
 
I
n
i
t
i
a
l
 
B
o
d
y
 
W
e
i
g
h
t
M
e
a
n
 
T
u
m
o
r
 
V
o
l
u
m
e
 
±
 
S
E
M
 
(
m
m
3
) A
B
0 5 10 15 20 25 30 35Cancer Chemother Pharmacol (2010) 65:923–930 929
123
Abraxane largely due to diVerences in their pharmaco-
kinetics.
Abraxane has an established role in the treatment of
breast cancer. We conclude from these studies that PGG–
PTX has the potential to out-perform Abraxane in enhanc-
ing the delivery of PTX to such tumors while at the same
time further reducing the toxicity of both single dose and
weekly treatment regimens.
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